(CSE: HUGE-NASDAQ: HUGE) Executive Co-Chairman and CEO Dr Raza Bokhari joined Steve Darling from Proactive Vancouver to talk about the company ringing the bell to open the trading day on the CSE.
Dr Bokhari also discussed their phase 1 first-in-human safety and tolerability trials for PP 101 micro-PEA
CSE:HUGE
Market: CSE
Market Cap: $49.56 m
Follow
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of FSD Pharma named herein, including the promotion by the Company of FSD Pharma in any Content on the Site, the Company receives from said issuer...
FOR OUR FULL DISCLAIMER CLICK HEREDeep dive
FSD Pharma is building a mammoth hydroponic indoor cannabis production...
Most read
FSD Pharma advancing its Phase 1 study in Australia
FSD Pharma Inc (CSE:HUGE) (NASDAQ:HUGE) CEO Raza Bokhari sat down with Proactive’s Christine Corrado at BIO CEO in New York. Bokhari says the Cobourg, Ontario-based company will initiate Phase 1 safety trials in patients for its lead drug candidate PP 101 micro-PEA in before the end of 1Q,...
3 weeks, 5 days ago
2 min read
Prev article
2 min read